唐氏综合征成年人中轻度认知障碍和阿尔茨海默病发病时的蛋白质组学特征。
Proteomic profiles of incident mild cognitive impairment and Alzheimer's disease among adults with Down syndrome.
作者信息
O'Bryant Sid E, Zhang Fan, Silverman Wayne, Lee Joseph H, Krinsky-McHale Sharon J, Pang Deborah, Hall James, Schupf Nicole
机构信息
Department of Pharmacology & Neuroscience I Institute for Translational Research University of North Texas Health Science Center Fort Worth Texas USA.
Vermont Genetics Network University of Vermont Burlington Vermont USA.
出版信息
Alzheimers Dement (Amst). 2020 May 21;12(1):e12033. doi: 10.1002/dad2.12033. eCollection 2020.
INTRODUCTION
We sought to determine if proteomic profiles could predict risk for incident mild cognitive impairment (MCI) and Alzheimer's disease (AD) among adults with Down syndrome (DS).
METHODS
In a cohort of 398 adults with DS, a total of n = 186 participants were determined to be non-demented and without MCI or AD at baseline and throughout follow-up; n = 103 had incident MCI and n = 81 had incident AD. Proteomics were conducted on banked plasma samples from a previously generated algorithm.
RESULTS
The proteomic profile was highly accurate in predicting incident MCI (area under the curve [AUC] = 0.92) and incident AD (AUC = 0.88). For MCI risk, the support vector machine (SVM)-based high/low cut-point yielded an adjusted hazard ratio (HR) = 6.46 ( < .001). For AD risk, the SVM-based high/low cut-point score yielded an adjusted HR = 8.4 ( < .001).
DISCUSSION
The current results provide support for our blood-based proteomic profile for predicting risk for MCI and AD among adults with DS.
引言
我们试图确定蛋白质组学特征是否能够预测唐氏综合征（DS）成年人发生轻度认知障碍（MCI）和阿尔茨海默病（AD）的风险。
方法
在一个包含398名DS成年人的队列中，共有n = 186名参与者在基线期及整个随访过程中被确定为无痴呆、无MCI或AD；n = 103名发生了MCI，n = 81名发生了AD。对先前生成的算法中储存的血浆样本进行蛋白质组学分析。
结果
蛋白质组学特征在预测MCI发生（曲线下面积[AUC]=0.92）和AD发生（AUC = 0.88）方面具有高度准确性。对于MCI风险，基于支持向量机（SVM）的高/低切点产生的调整后风险比（HR）= 6.46（< .001）。对于AD风险，基于SVM的高/低切点评分产生的调整后HR = 8.4（< .001）。
讨论
目前的结果为我们基于血液的蛋白质组学特征用于预测DS成年人发生MCI和AD的风险提供了支持。
Zotero 插件